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Abstract
STIM1 is an endoplasmic reticulum protein with a role in Ca2+ mobilization and signaling. As a sensor of
intraluminal Ca2+ levels, STIM1 modulates plasma membrane Ca2+ channels to regulate Ca2+ entry. In neuroblasto-
ma SH-SY5Y cells and in familial Alzheimer’s disease patient skin fibroblasts, STIM1 is cleaved at the transmem-
brane domain by the presenilin-1-associated γ-secretase, leading to dysregulation of Ca2+ homeostasis. In this report,
we investigated expression levels of STIM1 in brain tissues (medium frontal gyrus) of pathologically confirmed
Alzheimer’s disease patients, and observed that STIM1 protein expression level decreased with the progression of
neurodegeneration. To study the role of STIM1 in neurodegeneration, a strategy was designed to knock-out the
expression of STIM1 gene in the SH-SY5Y neuroblastoma cell line by CRISPR/Cas9-mediated genome editing, as
an in vitro model to examine the phenotype of STIM1-deficient neuronal cells. It was proved that, while STIM1 is
not required for the differentiation of SH-SY5Y cells, it is absolutely essential for cell survival in differentiating
cells. Differentiated STIM1-KO cells showed a significant decrease of mitochondrial respiratory chain complex I
activity, mitochondrial inner membrane depolarization, reduced mitochondrial free Ca2+ concentration, and higher
levels of senescence as compared with wild-type cells. In parallel, STIM1-KO cells showed a potentiated Ca2+ entry
in response to depolarization, which was sensitive to nifedipine, pointing to L-type voltage-operated Ca2+ channels
as mediators of the upregulated Ca2+ entry. The stable knocking-down of CACNA1C transcripts restored mitochon-
drial function, increased mitochondrial Ca2+ levels, and dropped senescence to basal levels, demonstrating the
essential role of the upregulation of voltage-operated Ca2+ entry through Cav1.2 channels in STIM1-deficient SH-
SY5Y cell death.
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Key messages
& STIM1 protein expression decreases with the progression of neurodegeneration in Alzheimer’s disease.
& STIM1 is essential for cell viability in differentiated SH-SY5Y cells.
& STIM1 deficiency triggers voltage-regulated Ca2+ entry-dependent cell death.
& Mitochondrial dysfunction and senescence are features of STIM1-deficient differentiated cells.
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FCCP Carbonyl cyanide 4-(trifluoromethoxy)
phenylhydrazone
RA Retinoic acid
SOC Store-operated Ca2+ channel
SOCE Store-operated Ca2+ entry
TMRM Tetramethylrhodamine methyl ester
Tg Thapsigargin
VOCC Voltage-operated Ca2+ channel
Introduction
STIM1 is a 685-aminoacid type I transmembrane protein
located in the endoplasmic reticulum (ER), with an essen-
tial role in Ca2+ mobilization and signaling. The Ca2+-
sensitive EF-hand domain at the N-terminus rules the con-
formational change in STIM1 when the intraluminal Ca2+
concentration drops below a threshold, and this change
triggers the clustering of STIM1 in plasma membrane-
ER juxtapositions where it binds store-operated Ca2+
channels in order to activate the Ca2+ influx pathway
termed store-operated Ca2+ entry (SOCE) (reviewed in
[1]). Therefore, STIM1 is critical as a regulator of Ca2+
mobilization, and its role has been studied in a number of
cellular events, including gene expression through the
calcineurin/NFAT or the calmodulin/CaMKII pathways
(reviewed in [2]), and cell proliferation [3], migration,
and metastasis [4–8].
Although the role of STIM1 in neuronal function is
still poorly understood, there is growing evidence for a
role of STIM1 in brain development and function. Early
reports described the pattern of STIM1 expression in brain
and its activation upon depletion of intracellular Ca2+
stores [9, 10]. It was later demonstrated that STIM1, to-
gether with dOrai1 (a store-operated Ca2+ channel activat-
ed by STIM1) were required for the normal activation of
motoneurons in Drosophila melanogaster, suggesting that
replenishment of intracellular Ca2+ stores is essential for
neuronal function [11]. A significant contribution was the
finding that STIM1 inhibits voltage-operated calcium
channels (VOCC), such as Cav1.2 [12, 13]. This inhibi-
tion is mediated by the same STIM1 domain that activates
SOCs, the STIM1-ORAI1 activating region (SOAR),
leading to the conclusion that STIM1 reciprocally acti-
vates SOCs and inhibits VOCCs. This inhibition is due
not only to direct binding of STIM1 to VOCCs but also to
enhancing internalization of the channel from the plasma
membrane [12].
In addition to Cav1.2, Cav3.1 has been shown to be
inhibited by STIM1. In cardiomyocytes, the knocking-
down of STIM1 expression increased the current density
of T-type voltage-operated Ca2+ channels, a result that was
explained by the fact that STIM1 also inhibits Cav3.1 by
direct interaction and by reducing the surface expression
of T-type VOCCs in HL-1 cells [14].
Furthermore, STIM1 has been studied as a possible regu-
lator of differentiation and axonal guidance. For instance,
STIM1 is actively recruited to the turning side of the
growth cone in response to brain-derived neurotrophic
factor (BDNF) [15], and SOCE regulates Ca2+ signaling
and guidance responses in Xenopus growth cones [16].
More recently, it was reported that mGluR1-dependent
synaptic potentials are strongly attenuated in the absence
of STIM1, and that STIM1 depletion in Purkinje cells
impairs cerebellar motor coordination [17]. On the con-
trary, transgenic mice overexpressing STIM1 exhibited
an improvement in contextual learning, with a significant
alteration of metabotropic glutamate receptor signaling
[18].
Given this collection of evidence, it would not be surpris-
ing if STIM1 deficiency were associated with a number of
pathologies. In this regard, the presenilin-1 (PSEN1)-asso-
ciated γ-secretase interacts with STIM1 in human neuro-
blastoma SH-SY5Y cells, familial Alzheimer’s disease
(FAD) patient skin fibroblasts, and mouse primary cortical
neurons [19]. Even more interestingly, STIM1 is cleaved at
the transmembrane domain, where STIM1 shows a target
sequence for γ-secretase, which is shared by the amyloid
precursor protein (APP). Indeed, neurons expressing mu-
tant PSEN1 show reduced SOCE and deterioration of den-
dritic spines [19]. Most AD cases, however, are sporadic or
late-onset. There is consensus that apolipoprotein E,
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epsilon 4 allele (APOE4) is the major risk factor for spo-
radic early and late-onset forms of AD (reviewed else-
where [20]). Nevertheless, increasing evidence supports a
central role of Ca2+ in neurodegenerative processes includ-
ing AD [21–23], and a review of the BCalcium Hypothesis
of Alzheimer’s disease and brain aging^ has recently been
updated [24] due to the growing evidence linking intracel-
lular Ca2+ perturbation with neurodegeneration. Besides,
there has been shown to be a Ca2+-dependent dysregula-
tion of the high affinity Ca2+ transporter plasma membrane
Ca2+-ATPase in AD brains and its inhibition by the
amyloid-β peptide (generated by aberrant cleavage of
APP) and tau, the main components of the two major path-
ological hallmarks of AD [25–27]. Also, a role has been
reported for PSENs in Ca2+ signaling via modulation of the
sarco(endo)plasmic reticulum Ca2+-ATPase [28]. The mo-
lecular mechanism that involves alteration of Ca2+ homeo-
stasis with AD is still far from clear, however, mainly due
to the lack of a model system that recapitulates Ca2+ dys-
regulation in neurodegeneration in the absence of muta-
tions in PSEN1, PSEN2, and APP, as occurs in late-onset
AD. It is known though that SOCE is decreased and
STIM1 and ORAI1 expression are downregulated in rat
hippocampal neurons after long-term culturing, an effect
that ends up with excessive Ca2+ overloading in the ER
and increased Ca2+ uptake by mitochondria, results that
might mimic in vivo neuronal aging [29]. In addition, it
has been shown that APP-deficient cells exhibit elevated
resting Ca2+ concentration within the ER and delayed
translocation of STIM1 to ORAI1 upon ER Ca2+ store
depletion [30].
Human neuroblastoma SH-SY5Y cells have been used for
many of the reports referred to above as they provide a model
for studying nerve cells, especially when neuritogenesis is
stimulated by widely used methods based on different neuro-
trophic factors, such as BDNF or growth differentiation factor
(GDNF). In addition, SH-SY5Y cells express multiple Cav
channels and auxiliary subunits [31], making this cell line a
suitable model for the study of the impact of STIM1 on neu-
ronal Ca2+ signaling.
In this report, we analyze STIM1 protein expression
levels in human brain tissues affected by increasing neuro-
degeneration associated with sporadic AD, as well as in
unaffected age-matched controls. The significant decline
in STIM1 expression observed in higher Braak stages led
us to study the role of STIM1 in SH-SY5Y cell differentia-
tion triggered by retinoic acid (RA) and BDNF, as well as
Ca2+ mobilization and mitochondrial function. We generat-
ed STIM1-deficient SH-SY5Y cells using a CRISPR-based
method to edit the STIM1 gene locus. Using these STIM1-
KO cells, we found that STIM1 is not required for differen-
tiation but is absolutely essential for cell survival in differ-
entiating cells. In these cells, STIM1 loss triggers
mitochondrial depolarization and senescence, two features
of cell death not previously reported for STIM1-deficient
cells. Finally, our results prove that the upregulation of
Ca2+ entry through Cav1.2 channels leads to cell death,
and that stable knocking-down of CACNA1C gene tran-




SH-SY5Y cells were purchased from European Collection of
Cell Cultures (ECACC) and distributed by Sigma-Aldrich (St.
Louis, MO, USA); Phoenix-AMPHO HEK293 were from
American Type Culture Collection (ATCC); all-trans-retinoic
acid, human brain-derived neurotrophic factor (BDNF), col-
lagen (type I), Dulbecco’s modified Eagle’s medium
(DMEM), DMEM:F-12 Ham medium, and nifedipine were
purchased from Sigma-Aldrich (St. Louis, MO, USA); fura-
2-acetoxymethyl ester (fura-2-AM) and BTP2 were from
Merck Millipore (Darmstadt, Germany); thapsigargin (Tg)
was from Abcam Biochemicals (Cambridge, UK); ML 218
and ω-conotoxin MVIIC were from Tocris Bioscience
(Bristol, UK); rhodamine 123, tetramethylrhodamine methyl
ester (TMRM), Hoechst 33258, Hoechst 33342, and 5-
dodecanoylaminofluorescein di-β-D-galactopyranoside
(C12FDG) were from Thermo Fisher Scientific (Waltham,
MA, USA); Clarity Max™ Western ECL substrate was from
Bio-Rad (Hercules, CA, USA).
Human tissue selection
Human tissues (medium frontal gyrus) were supplied by the
Netherlands Brain Bank (NBB, Amsterdam, The Netherlands)
and selected from six individuals diagnosed as having AD
(Braaks stages IV, V and VI, ages 84 ± 7) and from six
age-matched patients with clinically-diagnosed non-AD
degenerative conditions (Braak stage I). Procedures, infor-
mation – and consent forms of the NBB have been approved
by the Medical Ethics Committee of the Vrije Universiteit
Amsterdam Medical Centre.
Antibodies
The rabbit polyclonal anti-STIM1 antibody (raised against
the C-terminus) was from ProSci Inc. (Poway, CA, USA),
and the mouse monoclonal anti-STIM1 antibody (raised
against the N-terminus) was from BD Biosciences
(Franklin Lakes, NJ, USA); the mouse monoclonal anti-
tubulin beta 3, class III (TUBB3), and the mouse anti-
beta tubulin (clone TUB 2.1) were from Sigma-Aldrich
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(St. Louis, MO, USA); the mouse monoclonal p21 anti-
body (p21CIP1) and the mouse monoclonal anti-GAPDH
ant ibody were f rom Santa Cruz Bio technology
(Heidelberg, Germany). Secondary horseradish peroxidase
(HRP)-labeled antibodies were from Pierce (Thermo
Fisher Scientific, Waltham, MA, USA), or from Santa
Cruz Biotechnology (Heidelberg, Germany).
DNA constructs, transfection, and retroviral infection
DNA constructs for the generation of STIM1-KO (constructs
DU52282, DU52301) were described and validated in previ-
ous reports by our group [5, 32], and they can be requested on
the reagents website https://mrcppureagents.dundee.ac.uk/.
Transfection of cells with these DNA constructs was
performed with 1–2 μg plasmid DNA per 10-cm dish and
polyethylenimine (Polysciences Inc., Eppelheim, Germany)
in serum-containing medium.
The construct with the 29mer shRNA cloned into the
pRFP-C-RS plasmid to knock-down CACNA1C gene expres-
sion was purchased from OriGene (#TF314247-A). In this
case, retroviral infection and production were performed as
described previously [33]. Briefly, Phoenix amphotropic ret-
roviral packaging cells were transfected (10–12 μg per 10-cm
dish) with the pRFP-C-RS plasmid. At 24 and 48 h post-trans-
fection, SH-SY5Y cells were incubated with the virus-
containing medium with 4 μg/ml polybrene. The culture was
extended for an additional of 48 h, and puromycin selection
(2 μg/ml) was performed for 5–6 days.
The construct pcDNA-4mtD3cpv to measure mitochondrial-
free Ca2+ concentration was a gift from Amy Palmer and Roger
Tsien (Addgene plasmid # 36324) [34].
Human brain membranes preparation
and immunoblot analysis
Crude human membranes from brain tissues were prepared as
described previously [25]. Briefly, tissues were homogenized
in 10 mM HEPES/KOH, pH 7.4; 0.32 M sucrose; 0.5 mM
MgSO4; 0.1 mM phenylmethanesulfonyl fluoride (PMSF);
2 mM 2-mercaptoethanol; and protease inhibitor cocktail so-
lution (Roche Diagnostics, Mannheim, Germany). The ho-
mogenates were first centrifuged at 1500 g for 10 min, and
the supernatants were further centrifuged at 100,000 g for
45 min. The final pellets were resuspended in 10 mM
HEPES/KOH, pH 7.4, 0.32 M sucrose. Protein content was
determined using the Coomassie Protein Assay Reagent
(Thermo Fisher Scientific).
Culture and differentiation of SH-SY5Y cells
SH-SY5Y cells were cultured in DMEM with 10% (v/v) fetal
bovine serum (FBS), 2 mM L-glutamine, 100 U/ml penicillin,
and 0.1 mg/ml streptomycin in a humidified atmosphere of
95% air/5% CO2 at 37 °C. Cell culture dishes and glass cov-
erslips were treated with collagen type I solution (1.5 μg/ml)
for a minimum of 30 min at 37 °C prior to cell plating.
For triggering SH-SY5Y differentiation, we followed the
protocol described in [35]. Basically, cells were plated at a
density of 103–104 cells/cm2 onto collagen-coated 24-well
plates or 35 mm dishes (Corning Inc., Corning, NY, USA),
in DMEM supplemented with 10% FBS. Twenty-four hours
after plating, 10 μM all-trans-RA was added to the cell cul-
tures, and 2 days later the cells were washed with fresh medi-
um containing 10μMRA. Six days after the initial plating, the
cells were washed and 50 ng/ml BDNF was added to the cell
culture which was extended for 2–6 additional days in FBS-
free DMEM/F12 medium.
Generation of genetically modified cells using
CRISPR/Cas9 gene editing
CRISPR/Cas9 gene editing was performed as reported pre-
v ious ly [5 , 32] . Br ie f ly, the gu ide pa i r ( sense
5′-(G)AGATGACAGACCGGAGTCAT and antisense
5′-(G)AGTCCCTGTCATGGTGGTGT) was identified
using the Sanger Institute CRISPR web tool (http://www.
sanger.ac.uk/htgt/wge/find_crisprs). This pair targets the
exon 5 of the STIM1 locus (ENSG00000167323),
therefore targeting the transcriptional variants NM_
001277961.1, NM_001277962.1, and NM_003156.3. The
antisense dsDNA guide and the sense guide were cloned
into constructs DU52282 and DU52301, as described
previously [5, 32]. Transfected cells were selected with
puromycin (2 μg/ml) for 48 h, and individual clones were
analyzed by immunoblotting and sequencing. Genomic
DNA was isolated and the target site was amplified by
PCR (primer-fw: 5′-CAAGAGCTAGAAGTGTTCCT
GGG; primer-rv: 5′-CTTTGGTTTCCATGGCACAGC).
Sequencing of the PCR fragments from the STIM1-KO
cells was performed to characterize indels.
Lysis of cells and immunoblot
Cells were lysed in the following buffer: 50 mM Tris-HCl
(pH 7.5), 1 mM EGTA, 1 mM EDTA, 1% (w/v) Nonidet
P40, 1 mM sodium orthovanadate, 50 mM sodium fluo-
ride, 5 mM sodium pyrophosphate, 0.27 M sucrose, 0.1%
(v/v) 2-mercaptoethanol, 1 mM benzamidine, and 0.1 mM
phenylmethylsulfonyl fluoride. Clarification of samples
was performed after lysis with 0.75–1 ml of ice-cold lysis
buffer/dish and centrifugation at 4 °C for 15 min at
20,000 g. Samples were sonicated with five 10-s pulses
with a setting of 45% amplitude using a Branson Digital
Sonifier. Protein concentration was determined using the
Coomassie Protein Assay Reagent.
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Lysates (10–40 μg) were subjected to electrophoresis on
polyacrylamide gels (4–12% acrylamide) and subsequent
electroblotting to nitrocellulose membranes. Membranes were
blocked for 1 h at room temperature (RT) in blocking buffer:
TBS-T (Tris-buffered saline buffer, pH 7.5, with 0.2% Tween-
20) containing 10% (w/v) non-fat milk. Then the membranes
were incubated overnight with the specific antibody diluted in
blocking solution at 4 °C, washed, and then incubated with
anti-IgG horseradish peroxidase (HRP)-conjugated secondary
antibody (typically 1:10,000 dilution) for 1 h at RT. Dilutions
of primary antibodies were as follows: anti-STIM1 antibody
(1 μg/ml), anti-beta tubulin (clone TUB2.1, 1/3000 dilution),
anti-TUBB3 (0.5 μg/ml), anti-p21 (0.8 μg/ml), and anti-
GAPDH (0.025 μg/ml). In all cases, luminol substrate was
added to the membranes and the signal recorded with the
ChemiDoc XRS+ imager (BioRad). The recorded signal was
quantified by volumetric integration using ImageJ.
Assessment of mitochondrial morphology
and function
Mitochondrial morphology was evaluated by live imaging of
cells stained with rhodamine123 (Rhod123) as described pre-
viously [36]. Briefly, cells were incubated with 5 μM
Rhod123 for 10 min at 37 °C and then washed in
bicarbonate-free Leibovitz’s L-15 medium. Cells were live
imaged at 37 °C in an UNO-Okolab stage incubator.
Rhod123 was excited with a 465–495 nm excitation filter,
and emitted light was detected using a long-pass 515- to
555-nm barrier filter, using an ORCA-EM CCD camera at-
tached to a Nikon Ti-E inverted microscope (Nikon
Instruments Europe B.V., The Netherlands).
The mitochondrial inner membrane potential was assessed
with TMRM by flow cytometry (FCM) and confocal micros-
copy. For FCM, detached cells were incubated with 2 nM
TMRM in PBS for 30 min at 37 °C. Hoechst 33258 (1 μM)
was added to exclude dead cells from analysis. Then, 20,000
cells per sample were acquired using a MACSQuant VYB
flow cytometer (Miltenyi Biotech). Kaluza software
(Beckman Coulter) was used for data analysis. When confocal
microscopy was used, cells were stained with 10 nM TMRM
for 30 min at 37 °C. Counterstaining with Hoechst 33342 was
performed to facilitate visualization of nuclei. Time-lapse ac-
quisition was performed for 5–10 min, with time intervals of
2 min. In all cases, 10 μM of the mitochondrial uncoupling
agent FCCP was used to evaluate the specificity of staining
with TMRM. Imaging was done with a FV1000 confocal
microscope (Olympus) and fluorescence quantification with
FV10 software (Olympus).
The activity of the electron transfer chain complex I was
measured at 37 °C as in [37]. The assay buffer was 10 mM
Tris–HCl, 50 mM KCl, 1 mM EDTA, and 2 mM KCN (pH
7.4). The quinone CoQ1 (50 μM) was used as electron
acceptor. The concentration of cell lysate protein in the assay
ranged between 85 and 130 μg/ml. The reaction was initiated
by the addition of 75 μM NADH and monitored from the
linear decrease of absorbance at 340 nm over 10 min. Then,
rotenone (10 μg) was added, and the absorbance at 340 nm
was recorded for 10 min. The activity of electron transfer
chain complex I was calculated from the difference of the
steady-state slope before and after addition of rotenone and
expressed in nmol per min per mg of cell lysate protein using
an extinction coefficient for NADH of 6.2 mM−1 cm−1.
Bright-field microscopy, morphological
measurements, and MTT assay
To monitor morphology and measure the length of neurites,
cells were fixed with 4% paraformaldehyde in PBS for
15 min at RT and evaluated under bright-field microscopy
on a Nikon Ti-E inverted microscope. Measurement of
neurites was performed with the NIS-Elements Advanced
Research software (Nikon).
Viable cells were estimated by measuring the amount of
colored formazan from the reduction of 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) by via-
ble cells as described previously [38, 39].
Cell cycle distribution and senescence
For cell cycle analysis, detached cells were fixed in cold 70%
ethanol for 5 min. After washing in PBS, cells were resus-
pended in PBS with 0.5% propidium iodide and 1 μg/ml
RNAse and incubated in the dark for 2 h with gentle agitation.
Cell cycle analysis was performed using a MACSQuant VYB
flow cytometer (Miltenyi Biotech), with discrimination of
doublets and acquiring > 20,000 cells per sample. To study
senescence, detached cells were stained with 1 μM C12FDG
in PBS for 30 min at 37 °C in the dark with gentle agitation.
After washing in PBS, cells were resuspended in PBS with
1 μMHoechst 33258 and analyzed by FCM in aMACSQuant
VYB flow cytometer (Miltenyi Biotech), acquiring a mini-
mum of 20,000 cells per sample.
Cytosolic- and mitochondrial-free calcium
concentration measurement
Cytosolic-free calcium concentration ([Ca2+]i) was measured
in fura-2-AM-loaded cells as described elsewhere [4, 5, 40].
Excitation fluorescence wavelengths were selected with 340/
26 and 387/11 nm filters (Semrock), and emission fluores-
cence with a 510/10 nm filter. All measurements were per-
formed at 36–37 °C. Excitation/emission conditionswere con-
trolled by the NIS-Elements AR software.
Depletion of Ca2+ stores was triggered by incubating cells
with 1 μM Tg in Ca2+-free HBSS with the following
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composition: 138 mM NaCl; 5.3 mM KCl; 0.34 mM
Na2HPO4; 0.44 mM KH2PO4; 4.17 mM NaHCO3;
4 mM Mg2+ (pH = 7.4). SOCE was measured by monitoring
the increase of the [Ca2+]i after the addition of 2 mM CaCl2 to
the Tg-containing medium.
[Ca2+]i upon depolarizing conditions was measured in
Ca2+-containing HBSS assay medium (1.26 mM CaCl2).
To trigger plasma membrane depolarization, HBSS with
90 mM KCl + 5 mM CaCl2 was added to cells for 1 min,
and then the cells were returned to the initial Ca2+-contain-
ing HBSS medium with 5.33 mM KCl. When required,
Ca2+ channel inhibitors were added from a stock solution
dissolved in water or DMSO. Calibration of the fura-2 ratio
signal was performed by adding 5 μM ionomycin + 5 mM
EGTA to cells in Ca2+-free HBSS (to assess Rmin), follow-
ed by 5 μM ionomycin + 5 mM Ca2+ (Rmax). [Ca2+]i was
calculated as [Ca2+]i = (R-Rmin)/Rmax-R) × Kd × (Sf2/
Sb2), where Sf2 and Sb2 correspond to the emission of fluo-
rescence when the dye is excited at 380 nm under Ca2+-free
and Ca2+-saturating conditions [41]. The fura-2/Ca2+ disso-
ciation constant was 224 nM [41], and the ratio Sf2/Sb2 was
3.8 in our experimental settings.
Mitochondrial-free calcium concentration ([Ca2+]m) was
measured as described elsewhere [42]. Cells were transient-
ly transfected with the plasmid pcDNA-4mtD3cpv, and 48 h
later [Ca2+]m was assessed by measuring CFP, YFP, and
FRET efficiency between the two channels. Excitation and
emission fluorescence wavelengths were selected with the
dual CFP/YFP-2 × 2M-B filter set (Semrock). All measure-
ments were performed at 36–37 °C in Ca2+-containing
HBSS for 4–5 min. Spectral unmixing (i.e., subtracting the
bleedthrough from one channel into another) was performed
by determining the bleedthrough coefficients as described
in [42]. The background-corrected ratio, i.e., ratio =
(FRETROI − FRETbackground) / (CFPROI − CFPbakground)
was converted to [Ca2+]m as described in [42], using a dis-
sociation constant for Ca2+ = 0.76 mM. The FRET/CFP ra-
tio (R) was evaluated after calibrating the signal with the
subsequent addition of 5 μM ionomycin + 5 mM EGTA
(Rmin), followed by the addition of 5 μM ionomycin +
10 mM Ca2+ (Rmax).
Statistical analysis of data
Statistical analyses between pairs of data groups were done
using the Mann-Whitney test of data (non-parametric un-
paired t test). Analyses were performed with the GraphPad
software. Differences between groups of data were taken sta-
tistically significant for p < 0.05. The p values are represented
as follows: (*) p < 0.05, (**) p < 0.01, and (***) p < 0.001.
Results
STIM1 expression in AD-affected and control human
brain tissues
As stated above, a higher rate of cleaved STIM1 was
found in fibroblasts from patients with PSEN1-mutants
associated with FAD [19]. Because no information is
available regarding the most frequent form of the dis-
ease—the sporadic AD—we monitored total STIM1
levels in human brain tissues (medium frontal gyrus) from
patients diagnosed with AD at high Braak stages (IV–VI).
Six AD brain samples and six age-matched controls were
analyzed. Quantification of STIM1 protein levels, normal-
ized with β-tubulin, showed a significant decrease in total
STIM1 for all stages (Fig. 1), and a negative correlation
between increasing Braak stage and the STIM1 level, with
the later dropping to ~30% at Braak stage VI. This is a
novel observation in sporadic AD that fits well with the
proposal that STIM1 might be directly involved in the
pathogenesis of neurodegenerative diseases. Additional
model systems are required, however, to study this possi-
bility in depth.
Fig. 1 Expression levels of STIM1 in human tissue samples. a Samples
of medium frontal gyrus membranes (12 μg) from human tissues
characterized for diagnosis as non-AD control Braak stage I (first lane)
and AD-Braak stages IV, V, and VI, were electrophoresed in a 7.5% SDS-
PAGE gel, electrotransferred to nitrocellulose and immunostained with
anti-STIM1 antibody. A representative immunoblot from four assays is
shown. b Quantification of STIM1 protein level relative to β-tubulin is
shown as mean ± SE values (a.u., arbitrary units)
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STIM1 expression in differentiating SH-SY5Y cells
In order to study the role of STIM1 in neurodegeneration,
we followed a well-established protocol to trigger differ-
entiation of SH-SY5Y neuroblastoma cells differentiation
in vitro. Cultures were differentiated following the classi-
cal protocol with 10 μM retinoic acid (RA) and 50 ng/ml
BDNF [35]. Differentiation was evaluated by assessing
the level of the neuron-specific β-tubulin 3 (TUBB3) as
performed elsewhere [43]. In parallel, we evaluated the
length of neurites as a measurement of the level of differ-
entiation (Fig. 2a, b). In both cases, we found the expect-
ed increase in TUBB3 expression and neurite length, so
this protocol was followed for the differentiation in the
subsequent experiments. Using the same cultures, we
monitored the level of STIM1 expression and confirmed
that there is a marked increase of STIM1 expression in
differentiated SH-SY5Y cells. However, this greater ex-
pression did not correlate with an increase of SOCE in
differentiated cells (Fig. 2c). On the contrary, there was
a significant decrease of SOCE suggesting that the mon-
itored upregulation of STIM1 might be related to SOCE-
independent events during differentiation. Because our work
was focused on the role of decreasing levels of STIM1 in
neurodegeneration, we designed a strategy to knock-out
STIM1 gene expression, in order to evaluate the real contri-
bution of STIM1 to cell viability, using SH-SY5Y cells as an
in vitro model system.
Fig. 2 STIM1 expression during differentiation of SH-SY5Y cells. a
Top: SH-SY5Y cells were differentiated with RA + BDNF, and
bright-field microscopy images of cells were recorded (left panel,
non-differentiated; right panel, differentiated after 9 DIV). Bottom:
Neurite length was measured in undifferentiated cells (n = 52), and
differentiated cells (n = 45), from two independent cultures. Scale
bar = 100 μm. b Top: Expression of STIM1 and TUBB3 was
assessed by immunoblot from undifferentiated cells and cells
differentiated after 9–10 DIV with RA + BDNF. Level of GAPDH
was assessed as a loading control of the immunoblot. Bottom: The
exp r e s s i on o f ST IM1 and TUBB3 was quan t i f i e d by
immunoblotting with lysates from three independent assays. c
Store-operated Ca2+ entry was evaluated in undifferentiated (black
line) and differentiated cells (red line). Fura-2-loaded cells were
incubated in a Ca2+-free HBSS (assay medium), and 1 μM
thapsigargin (Tg) was added to the cells for 6 min. Ca2+ (2 mM
CaCl2) was finally added to the cells to evaluate the extension of
Ca2+-entry. The experiment was performed at controlled temperature
(36–37 °C). Data are presented as the mean ± s.d. of three
independent experiments (n > 60 cells for each condition)
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Generation of CRISPR/Cas9-mediated STIM1 gene
knock-out
CRISPR-Cas9 genome editing was used to edit exon 5 in the
STIM1 locus (ENSG00000167323). As our group has report-
ed recently [5, 32], this exon was shared by the known tran-
scriptional variants in STIM1 gene, and is therefore a preferred
target to knock-out the expression of STIM1 proteins. The
strategy depicted in Fig. 3a was intended to generate in-
frame indels within the target site in order to trigger transla-
tional frame shifting. After selecting puromycin-resistant
clones, the screening of genomic DNA was performed with
flanking primers surrounding the target site. This screening
revealed a positive clone with a 211 + 318 bp insertion,
therefore leading to premature translational STOP codons
in both alleles. Consequently, this clone showed no ex-
pression of STIM1 by an immunoblot performed with two
different antibodies raised against the N- and the C-
termini (Fig. 3b). The lack of STIM1 led to a significant
drop in the level of SOCE, which was assessed by the
classical Ca2+-added back assay after a short incubation
with thapsigargin, a sarco(endo)plasmic reticulum Ca2+-
ATPase inhibitor, in Ca2+-free medium. These results con-
firmed that the selected clone of cells was deficient in this
Ca2+-influx pathway (Fig. 3c). As a control of this experiment,
we measured SOCE in the presence of the SOCE inhibitor
BTP2 (also known as YM58483). In parallel, we measured
the steady state [Ca2+]i in wild-type and STIM1-KO cells in a
Ca2+-containing assay medium. We found that the absence of
STIM1 led to a significant decrease of this value, from 77.4 ±
10 nM for wild-type cells to 44 ± 4.4 nM in STIM1-KO cells
(Fig. 3d), suggesting that STIM1 regulates basal [Ca2+]i.
Then, we proceed to differentiate control SH-SY5Y and
STIM1-KO SH-SY5Y cells following the protocol described
above.We found that STIM1-KO cells differentiated similarly
to the parental cell line. The length of neurites reached similar
levels in wild-type and STIM1-KO cells (Fig. 4a). In addition,
the assessment of TUBB3 levels by immunoblot showed no
statistically significant differences between the two cell lines
(Fig. 4b), supporting the conclusion that STIM1 is not re-
quired for the full differentiation of SH-SY5Y cells in re-
sponse to RA + BDNF.
Loss of STIM1 severely affects cell viability
in differentiated cells
Although differentiation was unaffected by the loss of
STIM1, a drop in cell viability was observed in STIM1-
KO cells, a drop which was statistically significant for dif-
ferentiated cells (Fig. 5a). To study this cell death in depth,
we examined whether an alteration of cell cycle underlay
the effect on cell viability. The results indicated that there
were no significant differences in the cell cycle distribution
between undifferentiated wild-type and STIM1-KO cells
(Fig. 5b). On the other hand, during differentiation, an ac-
cumulation of cells at G0/G1 was observed, a common fea-
ture after treatment with RA for other cell types [44, 45].
Although the extent of the increase at G0/G1 was the same
in both cell lines, the reduction in the number of cells at S
phase was significantly greater in differentiated STIM1-KO
cells than in wild-type cells. This latter result also reflects
the differential arrest observed at G2/M which was signifi-
cantly greater for differentiated STIM1-KO cells than for
wild-type cells (Fig. 5b), a result that suggests a slowing-
down of the cell cycle at this transition in the absence of
STIM1. We also measured the level of haplodiploidy as an
index of apoptosis, finding no significant differences be-
tween wild-type and STIM1-KO cells (data not shown),
leading to the conclusion that this pathway has a minimal
contribution to the drop in cell viability observed during
differentiation.
Because of the increase in the level of cells at G2/M-
phase, we tested the hypothesis that the cell death in the
STIM1-KO case might be a consequence of an increase in
senescence. We therefore measured senescence by incubat-
ing cells with 5-dodecanoylaminofluorescein di-beta-D-
galactopyranoside (C12FDG), a fluorogenic substrate for
the senescence-associated beta-galactosidase activity [46],
and measuring the product by flow cytometry. The results
indicated a significant increase of cellular senescence in
differentiated STIM-KO cells (Fig. 5c), which explains the
drop in cell viability shown in Fig. 5a (MTT assay).
Fig. 3 Knockout of STIM1 expression by CRISPR/Cas9 D10A gene
editing. a Strategy for gene editing using CRISPR/Cas9 D10A in SH-
SY5Y cells. A pair of guide RNAs (sense and antisense) was designed to
trigger a double nick at exon 5 of the STIM1 locus. PAM sequences are
denoted in green font. Sequencing of a PCR product from the genomic
DNA of the selected clone revealed a 211 + 318 base-pair insertion at the
target site. The translated protein sequence is denoted in red font, with
premature stop codons at the end of the sequences of both alleles. b The
selected clone of cells was assessed for STIM1 expression by immunoblot,
using two different anti-STIM1 antibodies generated against C-terminal
and N-terminal epitopes. Anti-GAPDH antibody was used as loading
control. c Ca2+ entry was assessed as in Fig. 2, i.e., triggering the
emptying of intracellular stores with 1 μM Tg in Ca2+-free HBSS and
adding 2 mM Ca2+ back to the medium after store emptying. When
required, the SOCE inhibitor BTP2 (3 μM) was added together with Tg.
Data are presented as the mean ± s.d. of three independent experiments
(n = 85 cells for KO; n = 75 cells for wild-type; n = 42 cells for WT +
BTP2). d Steady-state cytosolic free Ca2+ concentration in WT and
STIM1-KO cells. Left panel: Fura-2-loaded cells were incubated in Ca2+-
containing HBSS (1.26 mM), and [Ca2+]i was measured as indicated in the
Methods section. After recording the F340/F380 ratio signal, the medium
was replaced by Ca2+-free HBSS to evaluate the contribution of
extracellular Ca2+ entry to the [Ca2+]i in resting conditions. Right panel:
After calibration of the fura-2 signal, the [Ca2+]i in resting conditions in
Ca2+-containing HBSS was 77.4 ± 10 nM for wild-type cells, and 44 ±
4.4 nM in STIM1-KO cells. Data are the mean ± s.d. of three
independent experiments (n = number of cells for each condition)
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Although senescence can be triggered by a wide range of
stress signals, it is widely accepted that the cyclin-
dependent kinase inhibitor 1 (the product of the gene
CDKN1A, also known as p21CIP1 or p21) is an essential
mediator, and therefore senescent cells show upregulated
expression of p21 [47]. This was the case for STIM1-KO
cells (Fig. 5d) which showed upregulation of p21 that was
statistically significant for differentiated cells.
J Mol Med (2018) 96:1061–1079 1069
Mitochondrial dysfunction in STIM1-KO cells
The initial viability test used in this study (MTT assay in
Fig. 5a) is based on the activity of dehydrogenases, mostly
from mitochondria, so we next tested the hypothesis of a
mitochondrial dysfunction triggered by the differentiation
in the absence of STIM1. The staining of mitochondria with
rhodamine 123 in order to monitor mitochondrial morphol-
ogy indicated the occurrence of extensive mitochondrial
fission in differentiated STIM1-KO cells (Fig. 6a), suggest-
ing the possibility of higher levels of mitochondrial depo-
larization in these cells. The analysis of the mitochondrial
inner membrane polarization was performed with
tetramethylrhodamine methyl ester (TMRM). A significant
drop in the level of TMRM-positive cells, i.e., with evident
mitochondrial depolarization, was found in differentiated
STIM1-KO cells (Fig. 6b), indicating a significant loss of
mitochondrial function. Undifferentiated cells showed sim-
ilar TMRM fluorescence levels in both the STIM1-KO and
the wild-type cell lines, in agreement with the results of cell
viability shown in Fig. 5a (data are shown as 1 DIV), and the
senescence data in Fig. 5c. This analysis was also performed
by confocal microscopy, and the fluorescence levels were
quantified from differentiated wild-type and STIM1-KO
cells, an experiment that revealed a drop in ~50% in
TMRM fluorescence in STIM1-deficient cells (Fig. 6c).
The mitochondrial uncoupler FCCP (10 μM) was added to
evaluate the background signal in our experimental setting.
Similarly, we assessed TMRM fluorescence in wild-type
and STIM1-KO cells by flow cytometry (Fig. 6d), in resting
conditions and after 10 min of incubation with 10 μM
FCCP. As noted above for confocal microscopy, FCCP
was used to evaluate the background signal of TMRM.
The results of the experiment confirmed the drop in mito-
chondrial polarization in STIM1-deficient cells to ~45% of
that found for wild-type cells.
Because mitochondrial inner membrane polarization re-
lies on efficient electron transport through respiratory
complexes, we measured the activity of complex I
(NADH-coenzyme Q oxidoreductase) (Fig. 7a), the most
important NADH oxidase activity in mitochondria, and
found more than 50% decrease of the activity of this
complex in STIM1-KO cells. This result demonstrated
that deficiency of STIM1 was accompanied by a major
impairment of mitochondrial function. The negative
charge of the membrane potential established by the re-
spiratory chain drives other important events, such as
Ca2+ uptake by the mitochondrial Ca2+ uniporter
(reviewed in [48]). Therefore, we measured the steady-
state mitochondrial-free Ca2+ concentration ([Ca2+]m) in
resting conditions using the genetically encoded Ca2+ sen-
sor 4mtD3cpv (Fig. 7b). The transient transfection of
wild-type and STIM1-KO cells with this indicator showed
that [Ca2+]m in STIM1-deficient cells was ~40% of that
found in wild-type cells (27.8 ± 22.8 μM for KO vs 66.4
± 10.9 μM for WT).
Fig. 4 STIM1 deficiency did not
modify markers of differentiation.
a STIM1-KO cells and the
parental cell line were
differentiated as indicated above,
and images of cells in culture
were recorded to assess neurite
length in undifferentiated cells
(top panels), and differentiated
after 12 DIVof treatment (bottom
panels). Scale bar = 200 μm.
Quantification of neurite length
revealed no differences between
wild-type and STIM1-KO cells.
Data are presented as the mean ±
s.d. of two independent
experiments (n = 50 cells for KO;
n = 45 cells for wt). b TUBB3
expression was studied by
immunoblot, as in Fig. 2, using
GAPDH as a loading control.
Differentiation was stopped at 9
DIVand the relative expression of
TUBB3 was assessed in three
independent experiments (data
are the mean ± s.d.)
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Contribution of L-type voltage-gated Ca2+ entry
to cell death in STIM1-KO cells
In the finding of the molecular mechanism underlying the ob-
served senescence, mitochondrial failure, and cell death trig-
gered by the loss of STIM1, we focused on the possibility of an
impairment in Ca2+ mobilization. As stated above, STIM1
inhibits Cav1.2 channels, and therefore the dihydropyridine-
sensitive voltage-gated Ca2+ entry. We therefore hypothesized
that STIM1-KO cells might have augmented Ca2+ entry
through this pathway that would be dysregulating Ca2+ ho-
meostasis. To test this hypothesis, we measured Ca2+ entry in
fura-2-loaded cells in response to a 1-min depolarization with
90 mMKCl. This experiment revealed increased Ca2+ entry in
Fig. 5 Loss of cell viability in differentiating STIM1-KO cells. a Cell
viability of wild-type (black bars) and STIM1-KO cells (gray bars) was
evaluated with an MTT assay at different stages of differentiation:
undifferentiated cells, 24 h in growing medium (1 DIV); 24 h in
growing medium + 2 days in differentiating medium (3 DIV); 24 h in
growing medium + 5 days in differentiating medium (6 DIV). Data are
presented as mean ± s.d. of three independent experiments, and results are
normalized to the values obtained from wild-type cells at 6 DIV. b The
analysis of the cell cycle was performed in undifferentiated (1 DIV) and
differentiated cells (6 days of differentiation), and the assay was
performed by staining fixed cells with propidium iodide and analyzing
cells by flow cytometry. The percentage of cells at G2/M phase is plotted
in the right panel to show the statistically significant increase of this phase
in STIM1-KO differentiated cells. In both panels, data are the mean ± s.d.
of three independent experiments. c Cells were cultured as indicated
above, and stained with C12FDG to evaluate senescence by flow
cytometry. The top panels show representative data histograms,
with data from unstained cells as negative control (in orange),
undifferentiated cells (pink), and differentiated cells after 6 DIV (blue).
The y-axis is the normalized cell number, and the x-axis is the
fluorescence intensity from C12FDG. Data of four independent
experiments are shown in the bottom panel as mean ± s.d. d Lysates
from cells in the experimental conditions described for panels (b, c)
were assessed for p21 expression by immunoblot. The top panel shows
a representative blot, with GAPDH as a loading control. The bottom
panel shows data of four independent experiments as mean ± s.d.
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response to depolarization with KCl in STIM1-KO cells com-
pared to wild-type cells (Fig. 8a). In order to evaluate the
contribution of dihydropyridine-sensitive voltage-gated Ca2+
channels (VOCCs) to this increase, we measured cytosolic
Ca2+ levels in the presence of 10 μM nifedipine, a concentra-
tion that blocks Ca2+ entry through L-type VOCCs [49, 50],
and we found that the Ca2+-entry sensitive to nifedipine was
~3-fold greater in STIM1-KO cells than in wild-type cells (Fig.
8a), a result that fits well with the function reported for STIM1
as a negative modulator of VOCCs [12, 13]. We also evaluated
the contribution of other VOCCs by studying the effect of
well-known inhibitors on the increase of [Ca2+]i under
depolarizing conditions (90 mM KCl). Neither ω-conotoxin
MVIIC, an inhibitor of N-, P-, and Q-type channels, nor ML
218, a highly specific inhibitor of T-type channels, prevented
the increase of [Ca2+]i in response to 90 mM KCl (Fig. 8a),
suggesting that the observed augmentedCa2+ influx in STIM1-
KO cells was due to L-type Ca2+ channels only.
To test whether the upregulation of this Ca2+ entry contrib-
uted to senescence and loss of mitochondrial inner membrane
potential, we knocked-down CACNA1C gene expression by
stable transfection of a specific short hairpin RNA (shRNA)
through retroviral infection of STIM1-KO cells. This long-
term silencing of CACNA1C gene transcripts reduced Ca2+
entry in response to depolarization (Fig. 8b), with the
Figure 7 Mitochondrial electron transport complex and mitochondrial
Ca2+ levels. a Total NADH oxidase activity and rotenone-sensitive
activity was assessed from differentiated SH-SY5Y cell lysates (WT
and STIM1-KO). Data are presented as the mean ± s.d. of two
independent experiments. Right panel shows the difference between
total activity and the remaining activity after rotenone addition to the
assay, i.e., the rotenone-sensitive NADH oxidase. b Wild-type and
STIM1-KO cells were transiently transfected for the expression of
the Ca2+ sensor 4mtD3cpv and 48 h later emission of fluorescence
was recorded for CFP, FRET (left and middle panels,), and YFP
channels to monitor photobleaching. FRET/CFP ratio signal (right
panel) was recorded for cells in Ca2+-containing HBSS for 4–5 min.
Calibration of FRET/CFP ratio to calculate Rmin and Rmax was
performed individually for every assay. [Ca2+]m data are presented as
the mean ± s.d. of seven independent experiments
Fig. 6 Loss of mitochondrial function in STIM1-KO differentiated
cells. a Cells, differentiated as indicated in Fig. 2, were stained
with rhodamine 123 in phenol red and serum-free medium, and
observed under epifluorescence. Samples, in bicarbonate-free
Leibovitz’s L-15 medium, were live-cell imaged at 37 °C in an
UNO-Okolab stage incubator and analyzed with a Plan
Apochromat × 100 (NA 1.45) oil immersion objective. Z-sections
(0.2-μm steps) were recorded, and after deconvolution, the total
projection was analyzed to observe mitochondria morphology.
Representative images from two independent experiments are
shown (> 20 cells per condition). Dashed line depicts nuclear
envelope. Scale bar = 10 μm. b Cells, under the experimental
conditions described for panel (a), were stained with TMRM, and
the fraction of positively TMRM-stained cells was analyzed by
flow cytometry. Data are presented as mean ± s.d. of three
independent experiments. c Cells were cultured on glass
coverslips and stained with TMRM. Cells were visualized under
confocal microscopy to evaluate the intensity and morphology of
staining in resting conditions. FCCP (10 μM) was added to assess
non-specific staining and loss of signal due to mitochondrial inner
membrane depolarization after 2 and 4 min. Hoechst 33342 was
used to stain cell nuclei (blue). Scale bar = 10 or 20 μm, as
indicated. TMRM fluorescence intensity from different ROIs was
quantified, and the data (mean ± s.d. of two independent
experiments) are shown as a box plot (right panel). d TMRM-
stained cells were analyzed by flow cytometry. Histograms (left
panel) depict the number of events (y-axis) and fluorescence
intensity (x-axis) for wild-type and STIM1-KO cells before and
10-min after addition of 10 μM FCCP. Total fluorescence data of
two independent experiments are shown in the right panel bar chart
as mean ± s.d.
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nifedipine-sensitive Ca2+ entry being similar to that found in
wild-type cells, confirming the functional knock-down of
Ca2+ influx through L-type VOCCs. As a result, the level of
senescence (i.e., C12FDG-positive cells) in differentiated
STIM1-KO cells fell back to the background level after silenc-
ing Cav1.2 expression (Fig. 8c). Moreover, the mitochondrial
inner membrane potential, measured with TMRM, was re-
stored in differentiated STIM1-KO cells when we knocked-
down CACNA1C gene expression (Fig. 8c). CACNA1C si-
lencing also restored mitochondrial complex I activity, which
reached values twofold higher than that observed in wild-type
cells (Fig. 8d), and [Ca2+]m was raised twofold up to 132.9 ±
46 μM when CACNA1C gene expression was silenced in
STIM1-depleted cells (Fig. 8e). The increase of the [Ca2+]m
was observed in parallel with a slight raise of the [Ca2+]i in
CACNA1C-depleted cells (Supp. File 1). However, the
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[Ca2+]i in STIM1-KO cells with silenced CACNA1C (54.3 ±
5.9 nM) was significantly lower than that observed for wild-
type cells (80.6 ± 4.9 nM), suggesting that the increase of
[Ca2+]m was not significantly influenced by the steady-state
value of the [Ca2+]i.
Altogether, these results confirmed that the upregulation of
Ca2+ transport through L-type VOCCs underlies mitochondri-
al dysfunction and senescence during differentiation of SH-
SY5Y cells in the absence of STIM1.
Discussion
Early-onset familial Alzheimer’s disease-3 (AD3) is caused
by heterozygous mutation in the PSEN1 gene on chromosome
14q24 (OMIM entry #607822, and references therein).
PSEN1 and PSEN2 are important determinants of γ-
secretase activity, which is responsible for the proteolytic
cleavage of the amyloid precursor protein (APP). Moreover,
the transmembrane domain of STIM1 is also a target for the
PSEN1-associated γ-secretase [19], and it has been reported
that fibroblasts from patients with familial AD show de-
creased levels of total STIM1 [19], and attenuation of SOCE
is observed in cells bearing PSEN1 mutations [51]. These
observations support a role for Ca2+ dysregulation in the path-
ogenesis of familial AD. However, the more frequent sporadic
late-onset AD is genetically complex, and therefore the lack of
suitable model animals makes the study of the involvement of
Ca2+ signaling in this form of the disease more challenging.
In this work, we report for the first time that a decrease of
STIM1 content is associated with neurodegeneration in sporadic
AD human brain. Thus, this type of study of cell behaviour with
decreased STIM1 levels is an experimental approach to under-
standing the role of Ca2+ signaling and Ca2+ homeostasis dys-
regulation in neurological diseases. In this regard, such genome
editing tools as CRISPR/Cas9 provide the opportunity to knock-
out specific genes with a minimal impact on the genome, i.e.,
without triggering genome instability. To this end, we used a
nickase version of the Cas9 nuclease, a strategy that reduces
the number of off-targets because it requires two independent
guide RNAs to define the target sequence to be edited. This
approach, which had been successfully developed in our labora-
tory for other cell types [5, 32], resulted in the loss of STIM1
protein expression in SH-SY5Y cells by the insertion of in-frame
premature STOP codons. With STIM1-deficient cells, we dem-
onstrate here that STIM1 is not directly involved in the differen-
tiation of neuroblastoma SH-SY5Y cells triggered by RA +
BDNF, although STIM1 is essential to sustain cell viability in
differentiated cells. Differentiated SH-SY5Y cells constitute a
model with which to study neuronal function in vitro, and there-
fore the fact that STIM1 is fully required to sustain the viability of
differentiated SH-SY5Y cells raises multiple questions regarding
the signaling pathways controlled by STIM1 in neurons.
The results shown in this report point to mitochondria func-
tion as a target of Ca2+ dysregulation triggered by the absence of
STIM1 in SH-SY5Y cells, similarly towhat it has been described
for fibroblasts from patients with loss-of-function mutations in
ORAI1 or STIM1 loci [52]. These fibroblasts showed reduced
expression of mitochondrial complexes CI and CIV and
supercomplex CICIII2, as well as reduced proton pumping rate
by the electron transport chain, limiting the mitochondrial mem-
brane potential. Similarly, a significant reduction in membrane
potential has been observed in this report for STIM1-KO cells
using the potential-sensitive dye TMRM. Ca2+ also regulates the
activity of three enzymatic reactions of the citric acid cycle:
isocitrate dehydrogenase, α-ketoglutarate dehydrogenase, and
pyruvate dehydrogenase, which is activated by theCa2+-sensitive
pyruvate dehydrogenase phosphatase (reviewed in [53]). Here,
we show that mitochondrial-free Ca2+ levels are significantly
reduced in STIM1-KO cells, in contrast to what it has been
reported in STIM1-deficient mouse embryonic fibroblasts using
Rhod-2-AM [54]. However, Ca2+ measurements obtained with
Rhod-2 are not accurate and the results obtained with this dye
should be taken with care, because they have a response to dy-
namic [Ca2+] changes qualitatively different to other Ca2+ sen-
sors, probably due to the generation of Rhod-2 derivatives during
light excitation [55]. Here, we report absolute [Ca2+]m levels
thanks to the use of the genetically encoded Ca2+ sensor
4mtD3cpv, that bypasses the methodological problems observed
with Rhod-2. Because Ca2+ stimulates the citric acid cycle, the
Figure 8 Increased cellular Ca2+ influx underlies mitochondrial failure
and augmented senescence. a Changes in cytosolic-free Ca2+
concentration were analyzed in fura-2-loaded cells. Cells in HBSS
containing 1.26 mM Ca2+ were subjected to 1-min depolarization
with 90 mM KCl (red line). CaCl2 in the HBSS was increased to
5 mM during depolarization to facilitate the Ca2+ influx recording.
In parallel experiments, 10 μM nifedipine was added to the assay
medium during the recording (black line). Right panel: the increase
of the F340/F380 ratio triggered by 90 mM KCl in the presence
of VOCCs blockers is shown as mean ± s.d. of 3 experiments
(a minimum of 70 cells per experimental condition). Final
concentrations: 10 μM nifedipine, 1 μM ω-conotoxin MVIIC, 3 μM
ML 218. b STIM1-KO cells, or STIM1-KO cells stably expressing a
specific shRNA to knock-down CACNA1C transcripts, were treated
as described in panel (a). The left panel shows a representative
experiment, and the bar chart of the right panel shows the increase in
the F340/F380 ratio evoked by depolarization (mean ± s.d. of two
independent experiments; n > 60 cells per condition). c Senescence
(left panel) and mitochondrial polarization (middle and right panels)
were assessed from differentiated cells after 6 DIV, staining with
C12FDG as described in Fig. 5c and TMRM as in Fig. 6b–d,
respectively. Data are mean ± s.d. of three independent experiments
(number of replicates is shown for each condition). d Rotenone-
sensitive NADH oxidase activity was assessed from differentiated
SH-SY5Y cell lysates (wild-type, STIM1-KO, and STIM1-KO +
shRNA for CACNA1C). Data are presented as the mean ± s.d. of
two independent experiments. e Cell were transiently transfected for
the expression of the Ca2+ sensor 4mtD3cpv. Mitochondrial [Ca2+]
was assessed as described in Fig. 7. Data of six independent
experiments are shown in the right panel bar chart as mean ± s.d.
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drop in [Ca2+]m monitored in STIM1-KO cells would limit the
NADH/FADH2 production. Together with this limited electron
donor supply, the inhibition of the complex I shown in Fig. 7
explains well the mitochondrial inner membrane depolarization
in STIM1-KO cells, an event that risks cell viability.
It is also important to consider that the increasing levels of
STIM1 observed during differentiation were not accompanied
by any increase in SOCE (see Fig. 2b, c). On the contrary, it is
remarkable that the increase of STIM1 in differentiated cells is
associated with a striking decrease of SOCE, suggesting a
non-canonical function of STIM1 in fully differentiated neu-
rons. Additional roles for STIM1 in fully differentiated cells
have been proposed, such as the control of neuronal excitabil-
ity and the intrinsic plasticity of Purkinje neurons [56] in
agreement with the results from transgenic mice overexpress-
ing STIM1 which show improved contextual learning [18].
Another role for STIM1 is the regulation of other non-SOC
Ca2+ channels, such as the voltage-operated Ca2+ channels
(VOCCs), Cav1.2 or Cav3.1, but STIM1 has also been impli-
cated in the regulation of the glutamate ionotropic receptor
AMPA type subunits 1/2 [57], and the glutamate metabotropic
receptor 1 (mGluR1) [17]. With regard to this set of channels
and receptors, it is known that STIM1 positively modulates
glutamate receptors. However, the molecular mechanism for
the regulation of mGluR1 and GluA1/2 remains to be eluci-
dated. On the contrary, it has been proposed that STIM1
downregulates voltage-operated Ca2+ entry mainly by inhibi-
tion of the Cav1.2 channel and triggering its internalization
[12, 13]. Our results support the conclusion that STIM1 is a
negative regulator of Cav1.2, and predict an augmented Ca
2+
entry through L-type VOCCs in those (patho-)physiological
conditions that develop with decreasing levels of STIM1. This
appears to be the case in AD according to recent findings with
familial AD patient fibroblasts [19] and the present findings
for sporadic AD. In addition, an elevated VOCC activity has
been recorded in CA1 neurons from hippocampal slices in
aged rats, an alteration that negatively regulates short-term
neuronal plasticity [58]. In this regard, compared with wild-
type mice, transgenic mice designed to develop accumulation
of amyloid β-peptide and selective hyperphosphorylated tau
pathology in hippocampal CA1 neurons (3 × TgAD mice)
showed age-related elevation of L-type Ca2+ channel current
density in these specific neurons, suggesting a contribution of
VOCCs to the selective vulnerability of CA1 neurons to tau
pathology, and a possible role to neuronal degeneration in AD
patients [59]. Accordingly, the long-term treatment of patients
with blockers of L-type VOCCs reduced the incidence of de-
mentia by 50% [60], further confirming earlier observations
that had associated hypertension with an increased risk of both
vascular dementia and AD [61]. Similarly, the prolonged treat-
ment with the VOCC blocker nimodipine ameliorated age-
related memory impairment in rats [62], and isradipine atten-
uated β-amyloid oligomer toxicity by reducing Cav1.2
expression in vitro and inhibiting Ca2+ influx [63], supporting
the feasibility of a therapeutic approach with dihydropyridines
in AD patients (reviewed in [64]).
Because a continuing decline of STIM1 levels is observed
in aged neurons [29], and also during neurodegeneration in
sporadic AD patients as reported here, the loss of STIM1
could be taken into consideration to explain the pathogenesis
of neurological diseases. Our results demonstrate that the loss
of STIM1 triggers cell death by upregulation of Ca2+ entry
through VOCCs. The silencing of a specific gene transcript
(CACNA1C for Cav1.2 channel) prevents the senescence trig-
gered by the absence of STIM1, restores the basal levels of
mitochondrial inner membrane potential and the mitochondri-
al respiratory complex I activity in STIM1-deficient cells, ful-
ly supporting a causal link between STIM1 reduction and cell
death. Altogether, the results prove that Cav1.2 upregulation is
essential to trigger cell death in STIM1-deficient cells, a pro-
posal that f i ts well with the protective effect of
dihydropyridines against neurodegeneration in AD patients.
Conclusions
Because STIM1 is a key regulator of Ca2+ channels, the
observation that there is a significant loss of STIM1 in hip-
pocampal human tissue from AD patients supports a role for
Ca2+ transport and signaling dysregulation in AD. Our re-
sults demonstrate that one of the most important down-
stream targets for the absence of STIM1 in differentiated
neuroblastoma cells is the upregulation of Ca2+ influx
through Cav1.2, which fully explains the Ca
2+ dysregula-
tion observed in hippocampal neurons from model animals
as well as the protective effect of VOCCs inhibition in AD
patients. In this regard, STIM1-KO cells constitute an in
vitro model with which to study the pathogenesis of the
disease, and will be useful to help understand the role of
STIM1 in the modulation of additional channels and path-
ways involved in neurodegeneration, with a possible impact
on the search for new therapeutic targets.
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